Intranasal Esketamine-dexmedetomidine Combination in Patients With Postherpetic Neuralgia
Key facts
- Who runs it
- Peking University First Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 80 people, planned
- Started
- Nov 2026
- Expected to end
- May 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Intranasal DEX-ESK combination
- Intranasal ESK alone
- Record updated
- 13 November 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 50 years
- Diagnosis of postherpetic neuralgia (PHN) requiring pharmacological analgesia, with a pain score ≥ 4 on the numerical rating scale (NRS)
- Provision of written informed consent
Who cannot take part
- Previous diagnosis of sleep apnoea, or high risk of moderate-to-severe sleep apnoea on the STOP-Bang assessment, or body mass index > 30 kg/m²
- Severe hepatic impairment (Child-Pugh class C); severe renal impairment requiring dialysis; or any ongoing life-threatening condition (e.g., myocardial infarction, cerebrovascular accident, transient ischaemic attack, or coronary stenting within the previous 3 months; active myocardial ischaemia; severe valvular disease; or end-stage renal disease not receiving dialysis)
- Unsuitability for intranasal administration due to nasal disorders (e.g., rhinitis, nasal polyps, or nasal obstruction from any cause)
- Inability to communicate owing to severe dementia, coma, or a language barrier
- History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis
- History of hyperthyroidism or phaeochromocytoma
- Hypersensitivity to dexmedetomidine and/or esketamine
- Participation in another clinical trial, or any other condition that, in the investigator's opinion, makes the patient unsuitable for inclusion
- Left ventricular ejection fraction (LVEF) < 30%; or sick sinus syndrome, severe sinus bradycardia (heart rate < 50 bpm), or second-degree or higher atrioventricular block without an implanted pacemaker; or systolic blood pressure < 90 mmHg before enrolment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Postherpetic neuralgia (PHN) is a chronic neuropathic pain syndrome suffered by patients with herpes zoster and often adversely affect patients' normal lives, leading to declines in sleep and quality of life. Ketamine/esketamine has been used for treatment of chronic pain but may produce adverse psychiatric reactions at slightly higher doses, including dissociative symptoms, hallucinations, and nightmares; the sedative effect of dexmedetomidine helps mitigate its psychiatric side effects. A previous study in orthopedic surgery patients also showed that dexmedetomidine combined with esketamine can significantly improve perioperative analgesia and sleep quality. The investigators hypothesize that intranasal administration of dexmedetomidine combined with esketamine in patients with postherpetic neuralgia can improve analgesic efficacy.
The 2 groups in the trial
- DEX-ESK groupTreatment being tested
For each administration: dexmedetomidine (1 spray = 0.05 ml = 25 μg) is administered as one spray into each nostril; after 1 minute, esketamine (1 spray = 0.05 ml = 1.25 mg) is administered alternately into each nostril, 4 sprays per nostril. Esketamine administration is repeated every 5 minutes until a total dose of 0.3 mg/kg is reached (using the number of sprays closest to the predetermined dose). If a dose is not tolerated, one administration may be omitted. Administer once daily for 4 consecutive days, with the same administration method as above.
Treatment: Intranasal DEX-ESK combination
- ESK groupExisting treatment, for comparison
For each administration: placebo (0.9% saline; 1 spray = 0.05 ml) is administered as one spray into each nostril; after 1 minute, esketamine (1 spray = 0.05 ml = 1.25 mg) is administered alternately into each nostril, 4 sprays per nostril. Esketamine administration is repeated every 5 minutes until a total dose of 0.3 mg/kg is reached (using the number of sprays closest to the predetermined dose). If a dose is not tolerated, one administration may be omitted. Administer once daily for 4 consecutive days, with the same administration method as above.
Treatment: Intranasal ESK alone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Intranasal Esketamine-dexmedetomidine Combination in Patients With Postherpetic Neuralgia: a Randomized, Double-blind, Active Drug-controlled Trial
- Record updated
- 13 November 2026